Advertisement

Topics

Capricor Therapeutics, Inc. Company Profile

02:28 EDT 23rd June 2018 | BioPortfolio

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.


News Articles [799 Associated News Articles listed on BioPortfolio]

Capricor Therapeutics, Inc.: Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018

LOS ANGELES, CA / ACCESSWIRE / April 6, 2018 / Capricor Therapeutics (NASDAQ: CAPR) today announces that AJ Bergmann, Chief Financial Officer will be a featured presenter at the MicroCap Conference...

Capricor Therapeutics initiates HOPE-2 trial in US

Capricor Therapeutics has initiated the HOPE-2 clinical trial of CAP-1002 to treat patients with advanced stages of Duchenne muscular dystrophy,...Read More... The post Capricor Therapeutics initiates...

Capricor's Duchenne muscular dystrophy drug gets FDA RMAT status

The FDA granted regenerative medicine advanced therapy designation to Capricor Therapeutics' CAP-1002, which is being develop -More- 

Capricor gets FDA RMAT designation for CAP-1002 to treat Duchenne muscular dystrophy therapy

The US Food and Drug Administration (FDA) has granted the regenerative medicine advanced therapy (RMAT) designation for Capricor Therapeutics’ investigational cell therapy for the treatment, CAP-100...

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2017 Results - Earnings Call Transcript

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q1 2018 Results - Earnings Call Transcript

Capricor Therapeutics (CAPR) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10

LOS ANGELES, May 04, 2018 (GLOBE NEWSWIRE) Read more...

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1238 Associated Companies listed on BioPortfolio]

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company wa...

Capricor, Inc.

Los Angeles-based Capricor is a biotechnology company that aims to create powerful, yet easy-to-administer cardiac stem cell treatments to regenerate the heart and improve its fun...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Capricor Therapeutics, Inc." on BioPortfolio

We have published hundreds of Capricor Therapeutics, Inc. news stories on BioPortfolio along with dozens of Capricor Therapeutics, Inc. Clinical Trials and PubMed Articles about Capricor Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Capricor Therapeutics, Inc. Companies in our database. You can also find out about relevant Capricor Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record